ocyan’s recent estimates regarding the interim survival: http://www1.investorvillage.com/smbd.asp?mb=971&mn=161016&pt=msg&mid=3287742 walkinizer’s lengthy estimate in May concerning the interim survival look: http://www1.investorvillage.com/smbd.asp?mb=971&pt=msg&mn=115125 Today, the CEGE CEO said that their 2Q08 interim look at the fully enrolled 600 patient Vital 1 trial in asymptomatic AIPC will be looking at Hazard Ratios since it is an event based trial. I went to an old review to see if I could figure that out, assuming perhaps incorrectly, that the allocated alpha that would determine success would be a p value, not a Hazard Ratio: http://aac.asm.org/cgi/content/full/48/8/2787#F1 However, this article, while helpful, didn’t address the issue directly. DNDN has, of course, disclosed that the Cox regression analysis, sometimes referred to as a Cox proportional hazards analysis, will be used as opposed to a Kaplan Meier log rank analysis for 9902b. Perhaps, you ,Walldiver, or ocyan, clarsterh, iwfal or some stat pro could clarify how “success”, if it occurs at the interim 9902b look, will be determined and described. TIA.
News 
Market Data 
Discover 
AI
